IDEAYA Biosciences, Inc. (IDYA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, IDEAYA Biosciences, Inc. reported revenue of $218.71M, up 3024.4% from the prior year. The company ran a net loss, with a net margin of -52.0%. It held $1.11B in total assets against $86.39M in total liabilities.
Key ratios (FY2025)
-72.8%
Operating margin
-52.0%
Net margin
-11.1%
Return on equity
+3024.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218.71M | $7.00M | $23.39M | $50.93M | $27.94M | $19.54M | $0 | — | — | — |
| Operating Income | -$159.31M | -$326.98M | -$134.43M | -$62.50M | -$50.27M | -$35.34M | -$44.27M | -$36.42M | -$14.44M | — |
| Net Income | -$113.70M | -$274.48M | -$112.96M | -$58.66M | -$49.76M | -$34.49M | -$41.98M | -$34.35M | -$11.86M | — |
| EPS (Diluted) | $-1.28 | $-3.36 | $-1.96 | $-1.42 | $-1.41 | $-1.40 | — | — | — | — |
| Total Assets | $1.11B | $1.12B | $649.32M | $387.97M | $381.35M | $298.27M | $113.00M | $96.54M | — | — |
| Total Liabilities | $86.39M | $64.94M | $28.23M | $38.51M | $79.83M | $100.00M | $12.60M | $7.10M | — | — |
| Shareholders' Equity | $1.02B | $1.06B | $621.09M | $349.45M | $301.51M | $198.27M | $100.40M | -$48.95M | -$15.74M | -$4.13M |
| Cash & Equivalents | $112.83M | $84.38M | $157.02M | $68.63M | $92.05M | $72.04M | $34.07M | $20.50M | $5.96M | — |
| Operating Cash Flow | -$71.10M | -$247.58M | -$115.22M | -$87.17M | -$55.78M | $55.46M | -$39.31M | -$27.62M | -$12.22M | — |
| Capital Expenditures | $2.37M | $3.86M | $2.37M | $3.44M | $2.64M | $493.0K | $1.35M | $1.71M | $1.76M | — |
| Shares Outstanding | 87.80M | 86.50M | 65.04M | 48.19M | 38.53M | 29.54M | 20.34M | 1.34M | — | — |